

Antibiotics 2021 Market Analysis

Giulio Filippo Tarro

The global [antibiotics market](#) was valued at USD 42,653.89 million in 2018, and is estimated to be valued at USD 56,369.92 million in 2024, witnessing a CAGR of 4.7%. The [Antibacterial Drugs market](#) is expected to cross US\$ 38 Billion by 2024 growing at a CAGR of 1% during the given forecast period. Rising pervasiveness of irresistible illnesses particularly in creating locales, for example, Asia Pacific and MEA is foreseen to contribute towards showcase development.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players include Allergan plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Forest Laboratories, Inc., GlaxoSmithKline plc, Merck & Co., Inc. Novartis AG, Pfizer, Inc., and Sanofi.

The antibiotics market generated sales of US\$42 billion in 2009 globally, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global [pharmaceutical market](#). However, the antibiotics market is maturing; it showed an average annual growth of 4% over the past 5 years, compared with a growth of 16.7% and of 16.4% for antiviral drugs and vaccines, respectively. Intent of valuing one's contribution to the field and after the idea of supporting and encouraging for more effective participation for the betterment of the industry as a whole. This concept shall encourage all the participants to accomplish more which will, in turn, promote the research networks and could lead towards a policy execution in fostering for a productive tomorrow. Considering the Scores given by the assessment committee and the Meeting Chair, the maximum scoring presentations shall be suggested for the following awards.

Over 15.0% of the passing's, in kids underneath the age of five, are assessed to be because of pneumonia and as indicated by the insights given by the WHO around 9.2 million passing's were recorded in 2015. Like tuberculosis, the most elevated commonness of the sickness is recognized to be in the South Asian and Sub-Saharan locales. At present, the required anti-infection

treatment is accessible just to 33% of the tainted populace, subsequently expanding the illness trouble.

The major driving factors of Antibacterial Drugs Market are as follows:

- There is a very high prevalence of infectious diseases.
- The research and development activities have increased.
- Product differentiation through various methods.
- Increased government support.

The restraining factors of Antibacterial drugs Market is as follows:

- Rise in [drug resistant species](#)
- Launch of the [generic drugs](#)
- Patent expiry

Importance and Scope

[Antibiotic resistance](#) is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.

Where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. Similarly, in countries without standard treatment guidelines, antibiotics are often over-prescribed by health workers and veterinarians and over-used by the public. Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.

Target Audience

Giulio Filippo Tarro

Professor, Biotechnologies and VirusSphere, World Academy Biomedical Technologies, Italy, E-mail: giuliotarro@gmail.com

- [Healthcare Students](#), Scientists, and professors
- Doctors
- [Microbiologist](#)
- Infectious diseases specialists
- [Antimicrobial scientists](#)
- [Pharmacists](#)
- Public health experts
- Laboratorist
- Bacteriology Researchers
- Faculty of bacteriology and infectious diseases
- Medical Colleges
- [Healthcare Associations](#) and [Societies](#)
- Business Entrepreneurs

Related Companies

1. [Gilead Sciences](#)
2. Pfizer
3. Abbott Laboratories
4. [Merck & Co](#)
5. Eli Lilly
6. [Astellas Pharma](#)
7. Teva Pharmaceutical Industries
8. Boehringer Ingelheim
9. Roche
10. Mylan
11. 3-D Matrix
12. Agilent
13. BeiGene
14. BioDuro

15. [Fosun Pharma](#)

Related Associations and Societies

1. [World Health Organization](#)
2. U.S. Food and Drug Administration (FDA)
3. Natural Resources Defense Council (NRDC)
4. Infectious Diseases Society of America
5. [World Health Assembly](#)
6. Center for a Livable Future (CLF)
7. The Humane Society of the United States (HSUS)
8. Alliance for the Prudent Use of Antibiotics
9. Civil Society Organisations
10. British Society for Antimicrobial Chemotherapy
11. Pediatric Infectious Diseases Society
12. [Royal Society of Medicine](#)
13. European Society of Clinical Microbiology and Infectious Diseases
14. CAESAR (Central Asian & Eastern European Surveillance of Antimicrobial Resistance)
15. WAAAR - World Alliance Against Antibiotic Resistance
16. ReAct – Action on Antibiotic Resistance
17. American Medical Association